CX Institutional Cuts Stock Position in Zoetis Inc. (NYSE:ZTS)

CX Institutional decreased its stake in Zoetis Inc. (NYSE:ZTSFree Report) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,470 shares of the company’s stock after selling 341 shares during the quarter. CX Institutional’s holdings in Zoetis were worth $1,474,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. State Street Corp increased its position in shares of Zoetis by 1.1% during the second quarter. State Street Corp now owns 19,630,557 shares of the company’s stock worth $3,380,578,000 after purchasing an additional 213,907 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Zoetis by 2.5% during the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock worth $2,147,730,000 after buying an additional 297,044 shares in the last quarter. Morgan Stanley raised its position in shares of Zoetis by 34.6% in the fourth quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after buying an additional 2,796,694 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Zoetis by 0.3% in the first quarter. Geode Capital Management LLC now owns 9,739,370 shares of the company’s stock worth $1,617,464,000 after buying an additional 27,097 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after acquiring an additional 196,771 shares in the last quarter. Institutional investors and hedge funds own 89.47% of the company’s stock.

Zoetis Stock Up 0.3 %

Zoetis stock opened at $168.90 on Friday. The firm has a market capitalization of $77.33 billion, a P/E ratio of 33.31, a P/E/G ratio of 2.57 and a beta of 0.87. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $151.03 and a twelve month high of $201.92. The stock’s fifty day simple moving average is $188.13 and its 200-day simple moving average is $182.87.

Zoetis (NYSE:ZTSGet Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the previous year, the business posted $1.15 EPS. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. As a group, equities analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Insider Activity

In related news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 2,209 shares of company stock worth $408,453. 0.12% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZTS. BNP Paribas initiated coverage on Zoetis in a report on Thursday, December 7th. They set an “outperform” rating and a $237.00 target price on the stock. Stifel Nicolaus lifted their price target on Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, January 12th. Piper Sandler raised their price objective on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. Jefferies Financial Group reissued a “buy” rating and issued a $230.00 price target on shares of Zoetis in a research note on Tuesday, December 19th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $224.33.

Read Our Latest Analysis on ZTS

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.